PL438023A1 - Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania - Google Patents

Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania

Info

Publication number
PL438023A1
PL438023A1 PL438023A PL43802321A PL438023A1 PL 438023 A1 PL438023 A1 PL 438023A1 PL 438023 A PL438023 A PL 438023A PL 43802321 A PL43802321 A PL 43802321A PL 438023 A1 PL438023 A1 PL 438023A1
Authority
PL
Poland
Prior art keywords
complex
mol
rna
polyethyleneimine
targeted liposomal
Prior art date
Application number
PL438023A
Other languages
English (en)
Other versions
PL245879B1 (pl
Inventor
Aleksander Franciszek Sikorski
Kazimierz Kuliczkowski
Aleksander CZOGALLA
Adam Konka
Original Assignee
Acellmed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acellmed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Acellmed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL438023A priority Critical patent/PL245879B1/pl
Priority to PCT/PL2022/000035 priority patent/WO2022255891A1/en
Publication of PL438023A1 publication Critical patent/PL438023A1/pl
Publication of PL245879B1 publication Critical patent/PL245879B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pierwszym przedmiotem wynalazku jest ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zawierająca miRNA skompleksowane z polikationem polietylenoiminą (PEI — Polyethyleneimine) 1:4 do 1:7, zamknięte w otoczce liposomowej, zawierającej 74,65 - 79,65 mol% uwodornionej fosfatydylocholiny sojowej (HSPC - hydrogenated soy L-α-phosphatidylcholine), 5 mol% dioleilofosfatydyloetanolaminy (DOPE - dioleoylphosphatidylethanolamine), 4,55 mol% distearoilofosfatydyloetanoloaminowej pochodnej glikolu polietylenowego 2000 w postaci soli amonowej, (DSPE-PEG — 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-20001]), 0,8 mol% maleimidowej pochodnej DSPE-PEG (DSPE-PEG-Mal), 10-15 mol% cholesterolu. Wynalazek obejmuje także zastosowanie oraz sposób wytwarzania ukierunkowanej liposomowej postaci kompleksu RNA-polietylenoimina.
PL438023A 2021-05-31 2021-05-31 Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania PL245879B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL438023A PL245879B1 (pl) 2021-05-31 2021-05-31 Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania
PCT/PL2022/000035 WO2022255891A1 (en) 2021-05-31 2022-05-31 A targeted liposomal form of an rna-polyethyleneimine complex, use of the form of the liposomal complex and a preparation process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438023A PL245879B1 (pl) 2021-05-31 2021-05-31 Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania

Publications (2)

Publication Number Publication Date
PL438023A1 true PL438023A1 (pl) 2022-12-05
PL245879B1 PL245879B1 (pl) 2024-10-28

Family

ID=84323488

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438023A PL245879B1 (pl) 2021-05-31 2021-05-31 Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania

Country Status (2)

Country Link
PL (1) PL245879B1 (pl)
WO (1) WO2022255891A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118453517B (zh) * 2024-07-15 2024-10-08 杭州珞米医疗科技有限公司 一种靶向结合ldlr的组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL407947A1 (pl) * 2014-04-18 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Ukierunkowana, liposomowa postać kompleksu oligonukleotyd-polietylenoimina, jej zastosowanie oraz sposób otrzymywania

Also Published As

Publication number Publication date
WO2022255891A1 (en) 2022-12-08
PL245879B1 (pl) 2024-10-28

Similar Documents

Publication Publication Date Title
Guimarães et al. Design of liposomes as drug delivery system for therapeutic applications
US5972379A (en) Liposome composition and method for administering a quinolone
Hope et al. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs
Balazs et al. Liposomes for use in gene delivery
AU2002305094C1 (en) Liposome composition for improved intracellular delivery of a therapeutic agent
ME02518B (me) Smeša lipozoma
PL438023A1 (pl) Ukierunkowana liposomowa postać kompleksu RNA-polietylenoimina, zastosowanie postaci kompleksu liposomowego oraz sposób otrzymywania
JP2009528340A5 (pl)
WO2004064731A3 (en) Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
WO2013008240A3 (en) Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
Fariya et al. Bolaamphiphiles: a pharmaceutical review
NZ703532A (en) Methods of treating arthritis
JP5856144B2 (ja) 経皮吸収用高分子‐リポソームナノ複合体組成物及びその製造方法
CN103561725B (zh) 用于肺递送的载体、导入剂及用途
CN103599069A (zh) 一种由pH敏感性多肽修饰的靶向脂质体
RU2010146482A (ru) Композиции для местного применения, содержащие противогрибковое и противовирусное средство
US20060128736A1 (en) Camptothecin-carboxylate formulations
CN102068698A (zh) 纳米疫苗及其制备方法
US8871252B2 (en) pH-responsive liposome
Düzgüneş et al. pH-sensitive liposomes: introduction of foreign substances into cells
CN116082184A (zh) 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用
ATE401057T1 (de) Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
PL383287A1 (pl) Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
WO2022015809A3 (en) Asymmetric charged vesicles and methods of preparing and use thereof
CN119604279A (zh) 脂质制剂